Arabic Arabic English English French French German German
dark

 aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

aTyr Pharma, Inc. today announced that the United States Adopted Names (USAN) Council and the World Health Organization’s (WHO) International Nonproprietary Name (INN) Expert Committee have selected the nonproprietary name efzofitimod for ATYR1923. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Yorkshire and Humber AHSN showcase innovations to senior NHS figures

Next Post

Evasc Neurovascular Announces Enrollment of First Patient in the French eCLIPs™ Safety, Feasibility and Efficacy Study (EESIS-FR)

Related Posts
Total
0
Share